business

Bristol-Myers Inks Up to $15 Billion Licensing Deal With Hengrui

Bloomberg Markets · May 12, 2026, 6:38 AM · Also reported by 3 other sources

Bristol-Myers Squibb Co. inked a collaboration and licensing deal with Jiangsu Hengrui Pharmaceuticals Co. that could be valued at as much as $15.2 billion, as the US drugmaker seeks to leverage China’s efficiency in early development.

Read full story on Bloomberg Markets → More top stories

Also covered by

Investing.com Hengrui Pharma shares surge on $1 bln Bristol-Myers partnership STAT News STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs ARY News Sony Music Publishing to buy recognition music catalog in $4 billion deal

Aggregated and edited by the Scoop newsroom. We surface news from Bloomberg Markets alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Bristol-Myers Inks Up to $15 Billion Licensing Deal With Hengrui

Also covered by

More in business